Levetiracetam Sun (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which modulates neurotransmitter release. This action stabilises neuronal firing and reduces hyper‑excitability, thereby decreasing the likelihood of seizure generation across various epilepsy syndromes.

The dosage of Levetiracetam Sun is determined by the prescribing clinician based on the patient’s age, weight, renal function and seizure type. Healthcare professionals adjust the infusion rate and total daily amount according to individual therapeutic needs.

Levetiracetam is classified as Pregnancy Category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. Use during pregnancy or lactation should be discussed with a healthcare provider, weighing potential benefits against unknown risks.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Compared with older antiepileptics such as carbamazepine or phenytoin, levetiracetam has a relatively favourable interaction profile, does not require routine serum level monitoring, and is associated with fewer enzyme‑inducing effects. Its rapid intravenous formulation also offers quick onset for acute seizure management.

The product should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Before administration, inspect the solution for particulate matter and ensure the vial is within the expiry date.

Levetiracetam Sun is given by intravenous infusion. The recommended infusion rate and total daily dose are set by the treating physician, who may choose a bolus or continuous infusion depending on the clinical scenario and patient tolerance.

Serious adverse events, although rare, include severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, blood dyscrasias, and emergence or worsening of suicidal thoughts or depression. Prompt medical attention is required if any of these symptoms occur.

Levetiracetam is contraindicated in patients with known hypersensitivity to levetiracetam or any component of the injection solution. Caution is advised in individuals with severe renal impairment, as dose adjustment may be necessary, and it should be used under medical supervision in pregnant or lactating women.